Sunrise Sets November Date For Hyperion Amended PMA Submission
This article was originally published in The Gray Sheet
Executive Summary
Sunrise Technologies has decided not to pursue a stability indication for its Hyperion laser thermal keratoplasty (LTK) ophthalmic laser system, in an amended premarket approval application to be filed in early November.
You may also be interested in...
Deficient Long-Term Data Render Sunrise Hyperopia Tool Not Approvable
Forty-six percent of the eyes treated with Sunrise Technologies' Hyperion laser thermal keratomileusis (LTK) system for hyperopia in clinical trials were under-corrected by greater than 1.00 diopter twenty-four months post-treatment, data contained in the firm's premarket approval application showed.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.